Portuguese 
English 
Spanish 
4 min of reading 
0 comments 
Russia Announced Advances in a Cancer Vaccine Called Enteromix, Cited as Highly Effective and Safe in Initial Tests. The Promise Is Free Access After Official Approval, but Details About Clinical Data Still Raise Questions.
The news that Russia may have an mRNA cancer vaccine called Enteromix, “100% effective,” ready for use and free for patients gained traction this Sunday (07).
What the official data shows so far is more cautious: the Russian federal agency FMBA reported that the vaccine has completed pre-clinical trials safely and with “high efficacy,” and that the file has been submitted to the Ministry of Health for usage authorization.
There is no confirmation of regulatory approval or immediate distribution start.
-
They seemed like common bones, but scientists were surprised to find a relic over 12,000 years old that dates back to before the Bronze Age.
-
With an almost perfect ring of 70 km visible from space, known as the “Eye of Quebec” and over 100 km in length, the Manicouagan Crater in Canada reveals the colossal mark left by a giant asteroid and has become one of the most impressive formations ever identified on the Earth’s surface.
-
Scientists have found in China dinosaur embryos dating back 190 million years in various stages of development, and the discovery still preserves traces of extremely rare proteins in the bones, something that could change what is known about life before hatching.
-
The CEO of Honor in Spain says that smartphones will change with AI, foldables, and even robot phones; the component crisis is making cheap models more expensive in 2026 and shifting the focus to premium.
What Was Announced and What Stage Is It In
The head of the FMBA, Veronika Skvortsova, stated during the Eastern Economic Forum held from September 3 to 6 that Enteromix is “ready for use” from a technical-scientific perspective, but awaits official approval.
According to her, pre-clinical studies indicated a reduction in tumor size and a slowing of its progression, varying from 60% to 80% depending on the disease characteristics, as well as a safety profile even in repeated applications.
Reports in the Russian press reiterate that the tests conducted so far were pre-clinical and demonstrated “high efficacy,” without publicly detailing study designs, inclusion criteria, or endpoints.
Some outlets add that the documentation has already been sent to the Ministry of Health, a necessary condition for any clinical use.
“100% Efficacy”: What the Headlines Say and What Is Known
Part of the international coverage echoed the expression “100% efficacy” as if there were complete clinical trials with that result.
Secondary sources, especially outside Russia, mention “success in tests” and, in some cases, treat efficacy as “clinical.”
However, reference Russian publications and TASS itself describe pre-clinical results, with significant responses, but do not use the “100%” metric for humans nor indicate the conclusion of clinical phases.
In summary, there are discrepancies between eye-catching titles and what the official communications actually support.
Additionally, a point of confusion arises in the terminology: while international reports characterize Enteromix as an mRNA vaccine, Russian materials related to the same oncolytic platform have been associated with different mechanisms in a hospital context.
This underscores the need for detailed technical documentation reviewed by peers.
There is currently no peer-reviewed scientific publication consolidating protocols, cohorts, and clinical outcomes for Enteromix.
How It Should Work and Who It Is Intended For First
Enteromix is described as a personalized vaccine developed from molecular information of the tumor itself, aligning with the trend of tailored immunotherapies.
The initial application aims at colorectal cancer, one of the most prevalent cancers worldwide.
In parallel, the FMBA mentioned working on versions for specific glioblastoma and melanomas.
These points consistently appear in official statements.
There are reports that, in 2025, the chief oncologist of the Russian Ministry of Health mentioned clinical studies with volunteers in the country.
Still, the September communications emphasize the pre-clinical stage as the basis for the “high efficacy” reported.
Without access to full trial records — phase, number of participants, centers, and methods — it is not possible to confirm, from open sources, that there are conclusive clinical results.
Regulatory Approval and Promise of Free Access
The prospect of free access has been mentioned by Russian authorities throughout the past year.
The idea is that, if approved, the vaccine will be offered at no cost to the patient, with state funding.
Previous estimates spoke of a high unit cost for the public system, but without direct charges to the user.
This promise, however, depends on regulatory approval, production scale, and indication criteria defined by the Ministry of Health.
In the short term, therefore, there is no confirmation of “free distribution to all cancer patients.”
What exists is the public commitment of free access in the Russian system after approval and initial prioritization of certain tumors, especially colorectal.
Until the regulatory agency publishes its decision and the usage protocol, Enteromix is not allowed for widespread application.
What Needs to Be Clarified Before Talking About “The End of Cancer”
There is a lack of peer-reviewed clinical data and complete records of human studies that confirm efficacy, safety, and survival benefit compared to standard treatment.
A metric of “100% efficacy” usually requires precise definitions of endpoint, population, and follow-up, something that has not appeared in the communications released so far.
There is also no confirmation of approval by the Russian Ministry of Health, nor an official timeline for national distribution.
In the meantime, media organizations outside Russia have been publishing optimistic summaries that generally do not provide the underlying technical documentation.
In summary, Enteromix represents a promising front in personalized oncological immunotherapy and may expand the arsenal against tumors such as colorectal.
Still, the information available this week indicates that the project is between the pre-clinical stage and regulatory procedures, with promises of free access contingent on approval.
What scientific evidence do you consider indispensable to assess whether an announcement like this corresponds to a real advance in clinical practice?
-
-
-
-
7 pessoas reagiram a isso.